Deksanabinol

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Deksanabinol
(IUPAC) ime
(6aS,10aS)-9-(Hidroksimetil)- 6,6-dimetil- 3-(2-metiloktan-2-il)- 6a,7,10,10a-tetrahidrobenzo [c]hromen-1-ol
Klinički podaci
Identifikatori
CAS broj 112924-45-5
ATC kod nije dodeljen
PubChem[1][2] 107778
ChemSpider[3] 96934
UNII R6VT8U5372 YesY
Hemijski podaci
Formula C25H38O3 
Mol. masa 386,567 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Deksanabinol (HU-211, ETS2101[4]) je sintetički kanabinoidni derivat koji je „neprirodni“ enantiomer potentnog kanabinoidnog agonista HU-210.[5] Za razliku od kanabinoidnih derivata, HU-211 ne deluje kao agonist kanabinoidnog receptora, nego kao NMDA antagonist.[6] On stoga ne proizvodi kanabisu slične efekte, ali je antikonvulsant i neuroprotektivan, te nalazi široku primenu u naučnim istraživanjima. On se takođe izučava za moguću primenu u tretmanu povrede glave, moždanog udara i kancera.[7][8][9] Klinička istraživanja su pokazala da je bezbedan.[10][11]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. e-therapeutics Clinical Development Pipeline
  5. Pop E (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design 6 (13): 1347–60. PMID 10903397. doi:10.2174/1381612003399446. 
  6. Feigenbaum JJ et al. (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America 86 (23): 9584–7. PMC 298542. PMID 2556719. doi:10.1073/pnas.86.23.9584. 
  7. Biegon A; Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research 17 (4): 275–80. PMID 7477742. 
  8. Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs : the Investigational Drugs Journal 6 (10): 976–9. PMID 14534855. 
  9. Vink R; Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 28–42. PMID 19110197. doi:10.1016/j.nurt.2008.10.036. 
  10. Maas AI et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". Lancet Neurol 5 (1): 38–45. PMID 16361021. doi:10.1016/S1474-4422(05)70253-2. 
  11. University of California, San Diego "Synthetic Cannabinoid May Be Used as Brain Cancer Treatment". (28 September 2012) Laboratory Equipment. Retrieved 28 September 2012.

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).